Cancer metastasis

The PD1-PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Temozolomide, Mevastatin, Cyclabezaprine, Hydralizine, SNX5422, Salinomycin (TMCHSS) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signaling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 9/October/2018, 12.16 pm
The PD1-PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Temozolomide, Mevastatin, Cyclabezaprine, Hydralizine, SNX5422, Salinomycin (TMCHSS) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signaling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 9/October/2018, 12.16 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction:What they say: A recent study from Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California, USA; Jonsson Comprehensive Cancer Center, David Geffen UCLA…

read more

The Ptpn2 pathway blockade enhances the efficacy of Cancer immunotherapy: Mifepristone, an abortion-promoting drug, inhibits the expression of protein tyrosine phosphatase PTPN2, increases interferon-IFNγ signaling, augments antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 9/October/2018, 11.24 am
The Ptpn2 pathway blockade enhances the efficacy of Cancer immunotherapy: Mifepristone, an abortion-promoting drug, inhibits the expression of protein tyrosine phosphatase PTPN2, increases interferon-IFNγ signaling, augments antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 9/October/2018, 11.24 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA; Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts…

read more

Awakening the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: Act1 (Adaptor for IL-17 receptors) increases the expression of tumor suppressors genes, such as BTG2, TIMP3, p53, TAp63, TAp73, INK4a/ARF, and others, induces regression of p53-mutated human tumors, via down-regulation of its target gene, 5/October/2018, 11.28 pm
Awakening the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: Act1 (Adaptor for IL-17 receptors) increases the expression of tumor suppressors genes, such as BTG2, TIMP3, p53, TAp63, TAp73, INK4a/ARF, and others, induces regression of p53-mutated human tumors, via down-regulation of its target gene, 5/October/2018, 11.28 pm 960 720 Dr Boomi's Genom-2-Discovery Center

From Significance of the study to Public health relevance:  Given that: (1) cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53…

read more

Awakening the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: Act1 (Adaptor for IL-17 receptors) increases the expression of tumor suppressors genes, such as ANP32A, VHL, p53,  p53, TAp63, TAp73, INK4a/ARF, and others, induces regression of p53-mutated human tumors, via down-regulation of its target gene, 2/October/2018, 11.56 pm
Awakening the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: Act1 (Adaptor for IL-17 receptors) increases the expression of tumor suppressors genes, such as ANP32A, VHL, p53,  p53, TAp63, TAp73, INK4a/ARF, and others, induces regression of p53-mutated human tumors, via down-regulation of its target gene, 2/October/2018, 11.56 pm 960 720 Dr Boomi's Genom-2-Discovery Center

On the eve of Mahatma Gandhi Birth Anniversary We wish everyone a happy Mahatma Gandhi Jayanti 2018. On this special occasion, we are happy to announce that Ideas posted today (02/October/2018) will be available to the use…

read more

Activating tumor suppressor gene network for cancer therapeutics: Pioglitazone (trade name: Actos), an anti-diabetic drug, increases the expression of tumor suppressors genes, such as LATS1, SMARCA4, p53,  p53, TAp63, TAp73, INK4a/ARF, and others, induces regression of p53-mutated human tumors, via down-regulation of its target gene, 28/September/2018, 7.49 am
Activating tumor suppressor gene network for cancer therapeutics: Pioglitazone (trade name: Actos), an anti-diabetic drug, increases the expression of tumor suppressors genes, such as LATS1, SMARCA4, p53,  p53, TAp63, TAp73, INK4a/ARF, and others, induces regression of p53-mutated human tumors, via down-regulation of its target gene, 28/September/2018, 7.49 am 960 720 Dr Boomi's Genom-2-Discovery Center

From Significance of the study to Public health relevance:  Given that: (1) cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53…

read more

Turning on the cancer-protecting tumor suppressor network in mutant p53-expressing human tumors: Andrographolide, isolated from Andrographis paniculata, increases the expression of tumor suppressors genes, such as BTG2, CADM1, p53,  p53, TAp63, TAp73, INK4a/ARF, and others, induces regression of p53-mutated human tumors, via down-regulation of its target gene, 28/September/2018, 7.14 am
Turning on the cancer-protecting tumor suppressor network in mutant p53-expressing human tumors: Andrographolide, isolated from Andrographis paniculata, increases the expression of tumor suppressors genes, such as BTG2, CADM1, p53,  p53, TAp63, TAp73, INK4a/ARF, and others, induces regression of p53-mutated human tumors, via down-regulation of its target gene, 28/September/2018, 7.14 am 960 720 Dr Boomi's Genom-2-Discovery Center

From Significance of the study to Public health relevance:  Given that: (1) cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53…

read more
Start Typing